The diagnosis of AD primarily relies on biomarkers such as amyloid-beta (Aβ) deposition, Tau pathology, and neurodegenerative or neuronal lesions (Jack et al., 2018), along with clinical manifestations including cognitive decline and psychoneurobehavioral changes (McKhann et al., 2011). This evidence concerns the gene MAPT and Alzheimer disease.